July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Endophthalmitis After Intravitreal Injection at an Academic Center
Author Affiliations & Notes
  • Rajinder Singh Nirwan
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Mohammad H Bawany
    University of Rochester School of Medicine and Dentistry, Rochester, New York, United States
  • David Diloreto
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Mina M Chung
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Rajeev S Ramchandran
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • angela bessette
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • David Kleinman
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Ajay E. Kuriyan
    Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States
  • Footnotes
    Commercial Relationships   Rajinder Nirwan, None; Mohammad Bawany, None; David Diloreto, None; Mina Chung, None; Rajeev Ramchandran, None; angela bessette, None; David Kleinman, None; Ajay Kuriyan, None
  • Footnotes
    Support  Research to Prevent Blindness (Flaum Eye Institute); NIH P30EY001319-35
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2036. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rajinder Singh Nirwan, Mohammad H Bawany, David Diloreto, Mina M Chung, Rajeev S Ramchandran, angela bessette, David Kleinman, Ajay E. Kuriyan; Endophthalmitis After Intravitreal Injection at an Academic Center. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2036. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the overall rate of post-intravitreal injection endophthalmitis and causative agents at an academic center. In addition, we report the management and long-term outcomes of these cases.

Methods : This is a retrospective consecutive case series of acute endophthalmitis (<4 weeks) following intravitreal injection at an academic center from January 2012 to November 2018. Cases were identified using billing and diagnosis codes for endophthalmitis occurring within 1 month of an intravitreal injection. The patients’ management, outcome, and the microbiologic data were recorded.

Results : Of 10,588 intravitreal injections, nine cases (0.085%; 95% confidence interval, 0.030%-0.141%) of post-intravitreal injection endophthalmitis were identified during the study period. The most common condition being treated was neovascular age-related macular degeneration (4/9; 44%). The most common medications identified were bevacizumab (3/9; 33%) and aflibercept (3/9; 33%). Three patients had negative culture. Six had positive culture, and coagulase-negative Staphylococci (3/6; 50%) was the most common organism isolated. Other isolates included Staphylococcus Aureus(1/6; 17%), Pseudomonas Aeruginosa(1/6; 17%), and Serratia Marcescens(1/6; 17%). Initial management consisted of vitreous tap and intravitreal antibiotics in 4 of 9 (44%) patients and vitrectomy and intravitreal antibiotics in 5 of 9 (56%) patients. Post-infection visual acuity outcomes ranged from 20/60 to no light perception, with one patient requiring enucleation.

Conclusions : The rate of endophthalmitis after intravitreal injection (0.085%) in our study is very low and consistent with previous studies. The most common bacterial isolate identified was coagulase-negative Staphylococci.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×